Letters to the editor

The multinational Conversations and Reactions Around Severe Hypoglycemia (CRASH) study: Impact of health care provider communications and recommendations on people with diabetes

ARTICLE INFO

Keywords
Diabetes
Severe hypoglycemia
Observational study
Survey

ABSTRACT

The multinational CRASH study found that substantive recommendations from health care providers were predictive of actions taken by people with diabetes during and after a severe hypoglycemic event, which highlights the importance of equipping people with actionable strategies to prevent and treat severe hypoglycemia should a severe hypoglycemic event arise.

Introduction

Hypoglycemia is a major barrier to achieve optimal glycemic control in people with diabetes (PWD) and places significant psychosocial burden on them and their families. We conducted a multinational, cross-sectional observational study, Conversations and Reactions Around Severe Hypoglycemia (CRASH), to understand the preparation for and management of severe hypoglycemia from the perspectives of both PWD and caregivers (CGs). The primary aim of this analysis was to explore the factors, including health care provider (HCP) communications and patient and disease characteristics, that were most predictive of actions taken by PWD during and after severe hypoglycemic events.

Material and methods

This study included CGs and adults with type 1 diabetes (T1DM) or insulin-treated type 2 diabetes (T2DM) who experienced ≥ 1 severe hypoglycemic event in the past 3 years. Severe hypoglycemia was defined as a low blood glucose event that PWD could not treat by themselves. Participants across 6 countries (US, UK, Germany, Canada, Spain, and France) completed a web-based questionnaire around their hypoglycemic experiences during July 2018 – February 2020. The survey questions were developed uniquely for this research, but included the Gold score[1], which asks PWD to rate the degree to which they are aware a hypoglycemic episode is commencing on a linear scale (1 = always aware, 7 = never aware). A rating of ≥ 4 indicates the PWD has ‘impaired awareness of hypoglycemia’. Study methodology and country-specific findings were reported previously[2-4].

Adjusted multivariable logistic regression models of PWD data were utilized to analyze predictors of actions taken during and after the most recent severe hypoglycemic event. Possible predictive variables were divided into seven variable blocks, ordered temporally as follows: [1] demographics, [2] diabetes and severe hypoglycemia history, [3] HCP communications on severe hypoglycemia and glucagon, [4] locations and symptoms of most recent severe hypoglycemic event, [5] recovery time and actions during most recent severe hypoglycemic event, [6] HCP recommendations made before most recent severe hypoglycemic event, and [7] HCP recommendations made after most recent severe hypoglycemic event (blocks 1–7, Table 1). Variable selection for the final multivariable model was performed using an iterative, hierarchical process, entering the variables per sets of variables (blocks) sequentially into the process, performing a stepwise selection (entry p < 0.25 and stay p < 0.10) within each block. Thereby, variables selected in previous blocks are always retained, even with p > 0.1 due to addition of the new variables in later blocks[5,6].

Results

Table 1 presents characteristics of study participants (N = 2132 [PWD 1141; CGs 991]) by diabetes types. The mean age of PWD was 48.3 (T1DM) and 55.4 (T2DM) years. Both people with T1DM and T2DM reported a median of 1 (Q1:1, Q3:2) severe hypoglycemic event in the past 12 months. Impaired hypoglycemia awareness, defined as Gold score ≥ 4, was reported in 33.6% and 23.6% of people with T1DM and T2DM, respectively.

With regards to HCP-patient communications, >70% of participants, both PWD and CGs, reported that HCPs did not discuss severe hypoglycemia with them at every visit, and approximately one-third of participants also reported that they did not discuss the most recent severe hypoglycemic event with HCPs. Notably, 25.4% of people with T1DM and 63.6% of people with T2DM reported ‘no’ to the question, ‘Has an HCP ever discussed glucagon with you?’ A significant proportion of all participants reported negative emotional impact while experiencing or witnessing the most recent severe hypoglycemic event (‘scared’ [62–77%], ‘unprepared’ [42–58%], ‘helpless’ [50–61%]).

Modeling data suggested that actions taken during and after the most recent severe hypoglycemic event were most significantly influenced by HCP recommendations compared to other variables examined. Specifically, PWD were significantly more likely to have received a glucagon injection during their recent severe hypoglycemic event (odds ratio [95% confidence interval]: 6.565 [3.533, 12.200]) or use professional health care resources (7.348 [4.965, 10.874]) during the severe hypoglycemic event if their HCPs recommended to do so. Correspondingly, PWD were more likely to change their behavior around glucagon (i.e.
Table 1
Sample Characteristics by Study Subgroup.

| Variables by Category | People with Type 1 Diabetes (N=633) | People with Type 2 Diabetes (N=508) | Caregivers Type 1 Diabetes (N=522) | Caregivers Type 2 Diabetes (N=469) | P-values
|------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|---------|
| [1]. Demographics      |                                     |                                     |                                     |                                     |         |
| Gender, female, n (%)  | 327 (51.7)                          | 186 (36.6)                          | 359 (68.8)                          | 304 (64.8)                          | <.0001  |
| Age, years, mean (SD)  | 48.3 (14.1)                         | 55.4 (12.7)                         | 47.0 (12.6)                         | 49.7 (14.0)                         | <.0001  |
| College degree, n (%)  | 461 (72.8)                          | 338 (66.5)                          | 365 (69.9)                          | 320 (68.2)                          | 0.1210  |
| [2]. Diabetes and SH History |                                     |                                     |                                     |                                     |         |
| Time since diabetes diagnosis, years, mean (SD) | 26.0 (15.5) | 13.8 (8.5) | 21.3 (16.7) | 18.0 (13.3) | <.0001  |
| Impaired awareness hypoglycemia (Gold score ≥4), n (%) | 213 (33.6) | 120 (23.6) | 182 (34.9) | 177 (37.7) | <.0001  |
| Number of SH events in the past 12 months, n (%) | 0.1471  |
| Mean (SD) | 3.3 (8.3) | 2.3 (4.9) | 3.3 (6.9) | 2.5 (5.3) |         |
| Median (Q1, Q3) | 1 (1, 2) | 1 (1, 3) | 1 (1, 2) | 1 (1, 2) |         |
| ≥3 | 147 (23.2) | 103 (20.3) | 136 (26.1) | 115 (24.5) |         |
| [3]. HCP Communication on SH and Glucagon |                                     |                                     |                                     |                                     |         |
| Discussion of SH with HCP, n (%) | <.0001  |
| At every visit | 221 (34.9) | 173 (34.1) | 140 (26.8) | 82 (17.5) |         |
| At some visits | 326 (51.5) | 251 (49.4) | 265 (50.8) | 236 (50.3) |         |
| Have not discussed | 86 (13.6) | 84 (16.5) | 117 (22.4) | 151 (32.2) |         |
| Ever discussed glucagon with HCP, YES, n (%) | 0.0245  |
| Number of SH events in the past 3 years | 0.0005  |
| Mean (SD) | 8.5 (17.1) | 5.3 (11.1) | 8.3 (17.4) | 5.9 (10.8) |         |
| Median (Q1, Q3) | 3 (1, 6) | 2 (1, 5) | 3 (1, 6) | 3 (2, 5) |         |
| [4]. Locations and Symptoms of Most Recent SH |                                     |                                     |                                     |                                     |         |
| Alone during SH, n (%) | 141 (22.3) | 186 (36.6) | 80 (15.3) | 74 (15.8) | <.0001  |
| At home during SH, n (%) | 517 (81.7) | 409 (80.5) | 429 (82.2) | 394 (84.0) | 0.5513  |
| Number of neuroglycopenic symptoms, mean (SD) | 4.9 (3.4) | 3.9 (2.9) | 5.1 (3.3) | 4.7 (3.5) | <.0001  |
| Number of autonomic symptoms, mean (SD) | 2.8 (2.0) | 2.7 (1.7) | 2.3 (1.8) | 2.5 (1.9) | <.0001  |
| [5]. Recovery Time and Actions During Most Recent SH |                                     |                                     |                                     |                                     |         |
| Time to recovery of SH, n (%) | 0.0005  |
| 00-15 minutes | 100 (16.4) | 78 (15.8) | 77 (15.1) | 38 (8.3) |         |
| 15-30 minutes | 217 (35.7) | 171 (34.7) | 196 (38.5) | 162 (35.4) |         |
| 30-60 minutes | 164 (27.0) | 135 (27.4) | 125 (24.6) | 129 (28.2) |         |
| 60 minutes or more | 127 (20.9) | 109 (22.1) | 111 (21.8) | 128 (28.0) |         |
| Used sugars during SH, n (%) | 522 (82.5) | 438 (86.2) | 421 (80.7) | 379 (80.8) | 0.0704  |
| Injected Glucagon during SH, n (%) | 85 (13.4) | 39 (7.7) | 77 (14.8) | 55 (11.7) | 0.0029  |
| Any health care contact during SH (called ambulance, called HCP, went to ER), n (%) | 125 (19.7) | 91 (17.9) | 135 (25.9) | 147 (31.3) | <.0001  |
| Scaled sum of acute emotional impact scores (0-100%), mean (SD) | 0.2529  |
| Scaled sum of life domain impacts (0-100%), mean (SD) | 0.9267  |
| [6]. HCP Recommendations Made Before Most Recent SH |                                     |                                     |                                     |                                     |         |
| Take sugar, n (%) | 488 (77.1) | 396 (78.0) | 351 (67.2) | 294 (62.7) | <.0001  |
| Inject glucagon, n (%) | 254 (40.1) | 64 (12.6) | 206 (39.5) | 70 (14.9) | <.0001  |
| Call HCP/ambulance or go to ER, n (%) | 136 (21.5) | 128 (25.2) | 154 (29.5) | 150 (32.0) | 0.0004  |
| [7]. HCP Recommendations Made After Most Recent SH |                                     |                                     |                                     |                                     |         |
| Change insulin regimen (timing/dosing), n (%) | 220 (34.8) | 208 (40.9) | 198 (37.9) | 189 (40.3) | 0.1267  |
| Change meal plan, n (%) | 77 (12.2) | 97 (19.1) | 76 (14.6) | 84 (17.9) | 0.0054  |
| Measure BG more often or get CGM, n (%) | 195 (30.8) | 177 (34.8) | 156 (29.9) | 128 (27.3) | 0.0782  |
| Start carrying sweets/sugar, n (%) | 138 (21.8) | 212 (41.7) | 113 (21.6) | 136 (29.0) | <.0001  |
| Obtain glucagon or keep it closer, n (%) | 62 (9.8) | 42 (8.3) | 58 (11.1) | 39 (8.3) | 0.3460  |
| PWD/CG Actions After Most Recent SH |                                     |                                     |                                     |                                     |         |
| Change insulin regimen (timing/dosing), n (%) | 235 (37.1) | 186 (36.6) | 238 (45.6) | 193 (41.2) | 0.0086  |
| Change meal plan, n (%) | 91 (14.4) | 119 (23.4) | 111 (21.3) | 118 (25.2) | <.0001  |
| Measure BG more often or get CGM, n (%) | 362 (57.2) | 260 (51.2) | 289 (55.4) | 240 (51.2) | 0.1062  |
| Start carrying sweets/sugar, n (%) | 291 (46.0) | 296 (58.3) | 240 (46.0) | 264 (56.3) | <.0001  |
| Obtain glucagon or keep it closer, n (%) | 57 (9.0) | 27 (5.3) | 65 (12.5) | 41 (8.7) | 0.0010  |

Acute Emotional Impact

(continued on next page)
To our knowledge, CRASH is the first multinational observational study providing insights on the preparation for and management of severe hypoglycemia from the perspectives of both PWD and CGs. Clinical guidelines recommend that conversations around hypoglycemia happen at every encounter.[7] Importantly, the results demonstrate that the substance of HCP-patient communications has a significant impact on patient actions. It is reassuring to find that the specific actions taken were those as recommended by HCPs during and after their most recent severe hypoglycemic event, suggesting that conversations and education are presumably the Gold score has only been validated for PWD.

This analysis included data from the US, UK, Germany, Canada, Spain, and France cohorts of the global CRASH study. Blocks for the multivariable model are represented by sections 1–7 of the table. Only PWD respondent data (columns 1 and 2) were modelled. Abbreviations: BG, Blood Glucose; CG, Caregiver; CGM, Continuous Glucose Monitoring; ER, Emergency Room; HCP, Health Care Provider; PWD, People with Diabetes; SD, Standard Deviation; SH, Severe Hypoglycemia, Q1, 1st quartile; Q3, 3rd quartile.

The results indicate that the most recent severe hypoglycemic event made them feel ‘scared’, ‘unprepared’, or ‘helpless’.

### Acknowledgments

Mark Peyrot provided consultation regarding the design of the statistical analysis and interpretation of results.

### Funding

This study was funded by Eli Lilly and Company.

### Author contributions

All authors substantially contributed to in drafting and critical revision of the work. In addition, each author has read and approved the work and assumes responsibility of the content of the work. FS and BDM were involved in the study concept and design. FS, ES, and BDM were involved in formulating the data analysis plan and ES conducted statistical analyses. All authors were involved in the interpretation of study results.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FS has received personal fees from Abbott, the Dutch Diabetes Research Foundation, the Dutch Medical Council for Health Research, Eli Lilly and Company, Novo Nordisk, Roche Diabetes Care, and Sanofi. DM, EM, KS, YY, and BDM are employees and shareholders of Eli Lilly and Company. ES was a HaPACS consultant at Lilly while the CRASH study was conducted and analyzed.

### References

1. Gold AE, MacLeod KM, Frier BM. Frequency of Severe Hypoglycemia in Patients With Type 1 Diabetes With Impaired Awareness of Hypoglycemia. Diabetes Care 1994;17(7):697–703.
2. Amundson-Bulos FJ, Artime E, Díaz S, Rubio M, Reviriego J, Mitchell B, et al. Conversations and Reactions Around Severe Hypoglycemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinología, Diabetes y Nutrición (English ed.) 2021;68 (3):557–66.
3. Mojadami D, Mitchell BD, Sparen E, et al. Conversations and Reactions Around Severe Hypoglycemia Study: Results of Hypoglycemia Experiences in Canadian Adults With Insulin-Treated Diabetes and Their Caregivers. Can J Diabetes. Apr 2021;45(3):226–42.
4. Mönig E, Sparen E, Osunili B, et al. Conversations and Reactions Around Severe Hypoglycemia (CRASH): Results from the German Cohort of a Global Survey of People with Type 1 Diabetes or Insulin-Treated Type 2 Diabetes and Caregivers. Exp Clin Endocrinol Diabetes. Dec 23. 2020.
Letters to the editor

Frank J. Snoek\textsuperscript{a}, Erik Spaepen\textsuperscript{b}, Donna Mojdami\textsuperscript{c}, Elisabeth Mönning\textsuperscript{d}, Kristen Syring\textsuperscript{e}, Yu Yan\textsuperscript{e}, Beth D. Mitchell\textsuperscript{f}\textsuperscript{*}

\textsuperscript{a} Amsterdam University Medical Centres, Vrije Universiteit Amsterdam, Netherlands

\textsuperscript{b} HaaPACS GmbH, Schriesheim, Germany

\textsuperscript{c} Eli Lilly Canada Inc, Toronto, Ontario, Canada

\textsuperscript{d} Lilly Deutschland GmbH, Bad Homburg, Germany

\textsuperscript{e} Eli Lilly and Company, Indianapolis, IN, USA

\textsuperscript{*} Corresponding author at: Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225.

E-mail address: mitchell_beth_d@lilly.com (B.D. Mitchell).